363:
underway in
Argentina, Brazil, Cuba, Indonesia, Philippines, Singapore, Thailand and Uruguay. 1,082 patients with NSCLC in stages IIIA (non-resectable), IIIB or IV will be evaluated in the study. The study is sponsored by Recombio in collaboration with Elea Laboratories (Argentina), CIM (Cuba), Europharma Laboratories (Brazil), Innogene Kalbiotech (Singapore) and several public research institutions.
362:
A randomized, multicenter, phase III study of active specific immunotherapy with
Racotumomab plus best support treatment, versus best support treatment in patients with advanced NSCLC who have achieved an objective response (partial or complete) or stable disease with standard first-line treatment is
320:
Gangliosides are concentrated on the surface of mammalian cells and play an important role in cell growth and differentiation. NGc gangliosides, however, are practically undetectable in healthy human tissues and fluids due to a genetic deletion in the human gene that encodes the enzyme responsible
332:
that mimics NGc gangliosides, thus triggering an immune response against the tumor antigen NGcGM3. Therefore, rather than being a passive antibody therapy, Racotumomab acts as a therapeutic vaccine. In melanoma, breast, and lung cancer patients, Racotumomab was able to elicit a specific immune
321:
for the synthesis of NGc, the CMP-N-acetyl hydroxylase. Nonetheless, the NGcGM3 ganglioside is highly expressed in several human cancers, including lung, breast, melanocytes, colon and neuroectodermal pediatric tumors, making this neoantigen an attractive target for cancer therapy.
333:
response that recognized and directly killed tumor cells expressing the neoantigen by a mechanism of oncotic necrosis. The specific expression of NGcGM3 in malignant cells reduces the potential risk of an immune cross-reactivity that could cause serious adverse effects.
527:"Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer"
282:
present on the cell surface of malignant cells from lung and breast, melanoma, as well as neuroectodermal pediatric tumors. Racotumomab has successfully completed a proof-of concept clinical trial in advanced non-small cell
271:. It induces the patient's immune system to generate a response against a cancer-specific molecular target with the purpose of blocking tumor growth, slowing disease progression and ultimately increasing patient survival.
290:
Racotumomab has been approved in two countries, Argentina and Cuba, for the treatment of recurrent or advanced NSCLC, or NSCLC independent of the disease stage when no other standard therapy can be administered.
299:
Racotumomab is administered in patients who have previously received the oncospecific treatment established in the oncological therapeutic standards (surgery, chemotherapy and radiation therapy). A racotumomab-
246:
for the treatment of solid tumors that is currently under clinical development by ReComBio (R and
Research in Computational Biology), an international public-private consortium with the participation of the
349:(local erythema, induration and pain), which disappear within 24–48 hours. Systemic reactions, such as flu-like symptoms and chills are less frequent, reversible, and self-limited.
78:
218:
766:
658:"Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism"
476:"Detection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancer"
31:
1175:
1751:
1707:
1376:
1596:
759:
341:
Racotumomab is well tolerated by patients. The overall toxicity of the vaccine has been classified as grade 1 and 2, according to the NCI
1233:
1160:
1065:
1090:
435:"An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients"
752:
1756:
1075:
264:
248:
1180:
1039:
135:
1724:
699:"Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data"
383:
818:
1761:
1283:
379:
342:
394:
Pharmaceutical product authorized under special conditions by the
Argentine Ministry of Health -Cert.N:57.031
1712:
1679:
1620:
1571:
1486:
1110:
576:
346:
260:
1650:
1640:
1610:
1401:
1346:
1273:
1263:
1140:
1625:
1614:
1576:
1466:
1451:
1381:
1361:
1356:
1135:
889:
304:
1476:
1336:
1105:
1070:
610:
1591:
1561:
1556:
1541:
1371:
1218:
1170:
1130:
775:
329:
99:
41:
24:
829:
1313:
864:
824:
656:
Hernández AM, RodrĂguez N, González JE, Reyes E, RondĂłn T, Griñán T, et al. (March 2011).
287:(NSCLC) and is currently being tested in a large, multinational study for the same indication.
1200:
1019:
730:
679:
638:
558:
507:
456:
68:
720:
710:
669:
628:
618:
597:
Chou HH, Takematsu H, Diaz S, Iber J, Nickerson E, Wright KL, et al. (September 1998).
548:
538:
497:
487:
446:
160:
108:
474:
Scursoni AM, Galluzzo L, Camarero S, Lopez J, Lubieniecki F, Sampor C, et al. (2011).
433:
Alfonso M, DĂaz A, Hernández AM, PĂ©rez A, RodrĂguez E, Bitton R, et al. (March 2002).
144:
697:
Vázquez AM, Hernández AM, MacĂas A, Montero E, GĂłmez DE, Alonso DF, et al. (2012).
614:
599:"A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence"
1718:
1684:
1351:
725:
698:
553:
526:
502:
475:
325:
243:
1745:
1566:
1421:
974:
809:
633:
598:
1581:
1546:
1531:
1526:
1521:
1516:
1491:
1446:
1441:
1436:
1431:
1416:
1303:
1278:
1258:
1120:
1085:
1024:
1004:
814:
799:
744:
307:
every 14 days for the first 2 months (5 doses), followed by monthly booster doses.
274:
Racotumomab triggers an immune response against the tumor antigen N-glycolyl (NGc)
1689:
1663:
1658:
1630:
1606:
1601:
1536:
1511:
1501:
1471:
1461:
1426:
1411:
1396:
1386:
1366:
1341:
1326:
1298:
1248:
1243:
1238:
1223:
1213:
1190:
1185:
1100:
1044:
1034:
1009:
999:
994:
989:
964:
939:
929:
924:
919:
909:
894:
879:
874:
859:
854:
844:
839:
834:
804:
451:
434:
284:
279:
603:
Proceedings of the
National Academy of Sciences of the United States of America
525:
van
Cruijsen H, Ruiz MG, van der Valk P, de Gruijl TD, Giaccone G (June 2009).
1635:
1586:
1551:
1481:
1456:
1406:
1391:
1331:
1321:
1293:
1268:
1208:
1150:
1145:
1080:
1060:
1014:
984:
979:
969:
959:
954:
944:
934:
904:
899:
869:
849:
199:
119:
674:
657:
623:
1506:
1496:
1288:
1253:
1228:
1165:
1125:
1115:
1095:
1029:
949:
914:
884:
715:
543:
268:
17:
734:
683:
562:
511:
460:
642:
492:
784:
421:
53:
252:
345:(version 3.0). Treatment is mostly associated with mild to moderate
46:
300:
256:
748:
275:
577:"Search of: racotumomab - List Results - ClinicalTrials.gov"
405:"Vaxira® | Deteniendo el proceso, prolongando la vida"
404:
225:
1672:
1649:
1312:
1199:
1053:
792:
783:
422:
Consorcio de investigaciĂłn, desarrollo e innovaciĂłn
198:
159:
154:
134:
118:
98:
93:
77:
67:
62:
52:
40:
30:
23:
107:
760:
8:
16:
592:
590:
789:
767:
753:
745:
724:
714:
673:
632:
622:
552:
542:
501:
491:
450:
143:
480:Clinical & Developmental Immunology
372:
15:
7:
14:
177:
171:
1752:Drugs not assigned an ATC code
265:National University of Quilmes
249:Center of Molecular Immunology
189:
183:
165:
1:
303:solution is administered by
452:10.4049/jimmunol.168.5.2523
259:(CIM) and researchers from
1778:
155:Chemical and physical data
1702:
1284:Mirvetuximab soravtansine
380:World Health Organization
215:
675:10.4049/jimmunol.1000609
624:10.1073/pnas.95.20.11751
347:injection site reactions
343:Common Toxicity Criteria
1680:Depatuxizumab mafodotin
1621:Tucotuzumab celmoleukin
1572:Rovalpituzumab tesirine
1487:Lorvotuzumab mertansine
1377:Clivatuzumab tetraxetan
716:10.3389/fonc.2012.00150
544:10.1186/1471-2407-9-180
261:Buenos Aires University
1641:Vorsetuzumab mafodotin
1597:Tacatuzumab tetraxetan
1402:Denintuzumab mafodotin
1347:Bivatuzumab mertansine
1274:Loncastuximab tesirine
1264:Indatuximab ravtansine
1141:Naptumomab estafenatox
1757:Monoclonal antibodies
1626:Vandortuzumab vedotin
1577:Sacituzumab govitecan
1467:Inotuzumab ozogamicin
1452:Gemtuzumab ozogamicin
1382:Cofetuzumab pelidotin
1362:Cantuzumab ravtansine
1357:Cantuzumab mertansine
1176:Nofetumomab merpentan
1136:Moxetumomab pasudotox
890:Glembatumumab vedotin
776:Monoclonal antibodies
703:Frontiers in Oncology
662:Journal of Immunology
439:Journal of Immunology
305:intradermal injection
1673:Chimeric + humanized
1477:Lifastuzumab vedotin
1337:Belantamab mafodotin
1106:Ibritumomab tiuxetan
1071:Anatumomab mafenatox
384:WHO Drug Information
278:(NGcGM3), a type of
1592:Sofituzumab vedotin
1562:Polatuzumab vedotin
1557:Pinatuzumab vedotin
1542:Oportuzumab monatox
1372:Citatuzumab bogatox
1234:Derlotuximab biotin
1219:Brentuximab vedotin
1171:Taplitumomab paptox
1161:Satumomab pendetide
1131:Nacolomab tafenatox
1066:Altumomab pentetate
615:1998PNAS...9511751C
493:10.1155/2011/245181
330:monoclonal antibody
316:Mechanism of action
242:) is a therapeutic
25:Monoclonal antibody
20:
1729:Never to phase III
1091:Capromab pendetide
865:Enfortumab vedotin
581:clinicaltrials.gov
324:Racotumomab is an
1739:
1738:
1698:
1697:
1020:Tisotumab vedotin
233:
232:
1769:
1762:Cuban inventions
1651:Rat/mouse hybrid
790:
769:
762:
755:
746:
739:
738:
728:
718:
694:
688:
687:
677:
653:
647:
646:
636:
626:
594:
585:
584:
573:
567:
566:
556:
546:
522:
516:
515:
505:
495:
471:
465:
464:
454:
430:
424:
419:
413:
412:
401:
395:
392:
386:
377:
229:
228:
221:
210:
208:
191:
185:
179:
173:
167:
147:
111:
58:NGNA ganglioside
21:
19:
1777:
1776:
1772:
1771:
1770:
1768:
1767:
1766:
1742:
1741:
1740:
1735:
1734:
1719:Clinical trials
1694:
1668:
1645:
1308:
1195:
1049:
779:
773:
743:
742:
696:
695:
691:
655:
654:
650:
609:(20): 11751–6.
596:
595:
588:
575:
574:
570:
524:
523:
519:
473:
472:
468:
432:
431:
427:
420:
416:
403:
402:
398:
393:
389:
378:
374:
369:
360:
358:Clinical trials
355:
339:
337:Adverse effects
318:
313:
297:
224:
222:
219:(what is this?)
216:
206:
204:
194:
188:
182:
176:
170:
150:
130:
114:
89:
12:
11:
5:
1775:
1773:
1765:
1764:
1759:
1754:
1744:
1743:
1737:
1736:
1733:
1732:
1731:
1730:
1727:
1716:
1710:
1704:
1703:
1700:
1699:
1696:
1695:
1693:
1692:
1687:
1685:Duvortuxizumab
1682:
1676:
1674:
1670:
1669:
1667:
1666:
1661:
1655:
1653:
1647:
1646:
1644:
1643:
1638:
1633:
1628:
1623:
1618:
1604:
1599:
1594:
1589:
1584:
1579:
1574:
1569:
1564:
1559:
1554:
1549:
1544:
1539:
1534:
1529:
1524:
1519:
1514:
1509:
1504:
1499:
1494:
1489:
1484:
1479:
1474:
1469:
1464:
1459:
1454:
1449:
1444:
1439:
1434:
1429:
1424:
1419:
1414:
1409:
1404:
1399:
1394:
1389:
1384:
1379:
1374:
1369:
1364:
1359:
1354:
1352:Brontictuzumab
1349:
1344:
1339:
1334:
1329:
1324:
1318:
1316:
1310:
1309:
1307:
1306:
1301:
1296:
1291:
1286:
1281:
1276:
1271:
1266:
1261:
1256:
1251:
1246:
1241:
1236:
1231:
1226:
1221:
1216:
1211:
1205:
1203:
1197:
1196:
1194:
1193:
1188:
1183:
1178:
1173:
1168:
1163:
1158:
1153:
1148:
1143:
1138:
1133:
1128:
1123:
1118:
1113:
1108:
1103:
1098:
1093:
1088:
1083:
1078:
1073:
1068:
1063:
1057:
1055:
1051:
1050:
1048:
1047:
1042:
1037:
1032:
1027:
1022:
1017:
1012:
1007:
1002:
997:
992:
987:
982:
977:
972:
967:
962:
957:
952:
947:
942:
937:
932:
927:
922:
917:
912:
907:
902:
897:
892:
887:
882:
877:
872:
867:
862:
857:
852:
847:
842:
837:
832:
827:
822:
819:+hyaluronidase
812:
807:
802:
796:
794:
787:
781:
780:
774:
772:
771:
764:
757:
749:
741:
740:
689:
668:(6): 3735–44.
648:
586:
568:
517:
466:
425:
414:
409:www.vaxira.com
396:
387:
371:
370:
368:
365:
359:
356:
354:
351:
338:
335:
326:anti-idiotypic
317:
314:
312:
309:
296:
293:
244:cancer vaccine
231:
230:
213:
212:
202:
196:
195:
192:
186:
180:
174:
168:
163:
157:
156:
152:
151:
149:
148:
140:
138:
132:
131:
129:
128:
124:
122:
116:
115:
113:
112:
104:
102:
96:
95:
91:
90:
88:
87:
83:
81:
75:
74:
71:
65:
64:
60:
59:
56:
50:
49:
44:
38:
37:
36:Whole antibody
34:
28:
27:
13:
10:
9:
6:
4:
3:
2:
1774:
1763:
1760:
1758:
1755:
1753:
1750:
1749:
1747:
1728:
1726:
1723:
1722:
1720:
1717:
1714:
1711:
1709:
1706:
1705:
1701:
1691:
1688:
1686:
1683:
1681:
1678:
1677:
1675:
1671:
1665:
1662:
1660:
1657:
1656:
1654:
1652:
1648:
1642:
1639:
1637:
1634:
1632:
1629:
1627:
1624:
1622:
1619:
1616:
1612:
1608:
1605:
1603:
1600:
1598:
1595:
1593:
1590:
1588:
1585:
1583:
1580:
1578:
1575:
1573:
1570:
1568:
1567:Rosmantuzumab
1565:
1563:
1560:
1558:
1555:
1553:
1550:
1548:
1545:
1543:
1540:
1538:
1535:
1533:
1530:
1528:
1525:
1523:
1520:
1518:
1515:
1513:
1510:
1508:
1505:
1503:
1500:
1498:
1495:
1493:
1490:
1488:
1485:
1483:
1480:
1478:
1475:
1473:
1470:
1468:
1465:
1463:
1460:
1458:
1455:
1453:
1450:
1448:
1445:
1443:
1440:
1438:
1435:
1433:
1430:
1428:
1425:
1423:
1422:Enoblituzumab
1420:
1418:
1415:
1413:
1410:
1408:
1405:
1403:
1400:
1398:
1395:
1393:
1390:
1388:
1385:
1383:
1380:
1378:
1375:
1373:
1370:
1368:
1365:
1363:
1360:
1358:
1355:
1353:
1350:
1348:
1345:
1343:
1340:
1338:
1335:
1333:
1330:
1328:
1325:
1323:
1320:
1319:
1317:
1315:
1311:
1305:
1302:
1300:
1297:
1295:
1292:
1290:
1287:
1285:
1282:
1280:
1277:
1275:
1272:
1270:
1267:
1265:
1262:
1260:
1257:
1255:
1252:
1250:
1247:
1245:
1242:
1240:
1237:
1235:
1232:
1230:
1227:
1225:
1222:
1220:
1217:
1215:
1212:
1210:
1207:
1206:
1204:
1202:
1198:
1192:
1189:
1187:
1184:
1182:
1179:
1177:
1174:
1172:
1169:
1167:
1164:
1162:
1159:
1157:
1154:
1152:
1149:
1147:
1144:
1142:
1139:
1137:
1134:
1132:
1129:
1127:
1124:
1122:
1119:
1117:
1114:
1112:
1109:
1107:
1104:
1102:
1099:
1097:
1094:
1092:
1089:
1087:
1084:
1082:
1079:
1077:
1074:
1072:
1069:
1067:
1064:
1062:
1059:
1058:
1056:
1052:
1046:
1043:
1041:
1038:
1036:
1033:
1031:
1028:
1026:
1023:
1021:
1018:
1016:
1013:
1011:
1008:
1006:
1003:
1001:
998:
996:
993:
991:
988:
986:
983:
981:
978:
976:
975:Pembrolizumab
973:
971:
968:
966:
963:
961:
958:
956:
953:
951:
948:
946:
943:
941:
938:
936:
933:
931:
928:
926:
923:
921:
918:
916:
913:
911:
908:
906:
903:
901:
898:
896:
893:
891:
888:
886:
883:
881:
878:
876:
873:
871:
868:
866:
863:
861:
858:
856:
853:
851:
848:
846:
843:
841:
838:
836:
833:
831:
828:
826:
823:
820:
816:
813:
811:
810:Ascrinvacumab
808:
806:
803:
801:
798:
797:
795:
791:
788:
786:
782:
777:
770:
765:
763:
758:
756:
751:
750:
747:
736:
732:
727:
722:
717:
712:
708:
704:
700:
693:
690:
685:
681:
676:
671:
667:
663:
659:
652:
649:
644:
640:
635:
630:
625:
620:
616:
612:
608:
604:
600:
593:
591:
587:
582:
578:
572:
569:
564:
560:
555:
550:
545:
540:
536:
532:
528:
521:
518:
513:
509:
504:
499:
494:
489:
485:
481:
477:
470:
467:
462:
458:
453:
448:
445:(5): 2523–9.
444:
440:
436:
429:
426:
423:
418:
415:
410:
406:
400:
397:
391:
388:
385:
381:
376:
373:
366:
364:
357:
352:
350:
348:
344:
336:
334:
331:
327:
322:
315:
310:
308:
306:
302:
294:
292:
288:
286:
281:
277:
272:
270:
266:
262:
258:
254:
250:
245:
241:
237:
227:
220:
214:
203:
201:
197:
164:
162:
158:
153:
146:
142:
141:
139:
137:
133:
126:
125:
123:
121:
117:
110:
106:
105:
103:
101:
97:
92:
85:
84:
82:
80:
76:
72:
70:
66:
63:Clinical data
61:
57:
55:
51:
48:
45:
43:
39:
35:
33:
29:
26:
22:
1582:Sibrotuzumab
1547:Parsatuzumab
1532:Otlertuzumab
1527:Odronextamab
1522:Ocaratuzumab
1517:Obinutuzumab
1492:Lumretuzumab
1447:Flotetuzumab
1442:Ficlatuzumab
1437:Farletuzumab
1432:Etaracizumab
1417:Emibetuzumab
1304:Zolbetuximab
1279:Margetuximab
1259:Girentuximab
1155:
1121:Minretumomab
1086:Blinatumomab
1025:Teprotumumab
1005:Seribantumab
830:Botensilimab
815:Atezolizumab
800:Adecatumumab
706:
702:
692:
665:
661:
651:
606:
602:
580:
571:
534:
530:
520:
483:
479:
469:
442:
438:
428:
417:
408:
399:
390:
375:
361:
340:
323:
319:
311:Pharmacology
298:
295:Medical uses
289:
273:
239:
238:(trade name
235:
234:
223:
217:
1715:from market
1690:Ontuxizumab
1664:Ertumaxomab
1659:Catumaxomab
1631:Vanucizumab
1611:+deruxtecan
1607:Trastuzumab
1602:Tigatuzumab
1537:Onartuzumab
1512:Nimotuzumab
1502:Milatuzumab
1472:Labetuzumab
1462:Imgatuzumab
1427:Epcoritamab
1412:Emactuzumab
1397:Dalotuzumab
1387:Dacetuzumab
1367:Cirmtuzumab
1342:Bevacizumab
1327:Alemtuzumab
1299:Ublituximab
1249:Ensituximab
1244:Ecromeximab
1239:Dinutuximab
1224:Carotuximab
1214:Bavituximab
1191:Tositumomab
1186:Tenatumomab
1156:Racotumomab
1101:Edrecolomab
1076:Arcitumomab
1045:Zalutumumab
1035:Vantictumab
1010:Sugemalimab
1000:Robatumumab
995:Rilotumumab
990:Ramucirumab
965:Panitumumab
940:Necitumumab
930:Mapatumumab
925:Lucatumumab
920:Lexatumumab
910:Istiratumab
895:Intetumumab
880:Flanvotumab
875:Figitumumab
860:Dusigitumab
855:Duligotumab
845:Daratumumab
840:Conatumumab
835:Cixutumumab
825:Balstilimab
805:Amivantamab
285:lung cancer
280:ganglioside
236:Racotumomab
211: g·mol
109:946832-34-4
94:Identifiers
69:Trade names
18:Racotumomab
1746:Categories
1636:Veltuzumab
1615:+emtansine
1587:Simtuzumab
1552:Pertuzumab
1482:Lintuzumab
1457:Glofitamab
1407:Elotuzumab
1392:Demcizumab
1332:Axatilimab
1322:Abituzumab
1294:Siltuximab
1269:Isatuximab
1209:Amatuximab
1181:Pintumomab
1151:Pemtumomab
1146:Oregovomab
1081:Bectumomab
1061:Abagovomab
1015:Tarextumab
985:Radretumab
980:Pritumumab
970:Patritumab
960:Olaratumab
955:Ofatumumab
945:Nesvacumab
935:Narnatumab
905:Iratumumab
900:Ipilimumab
870:Enoticumab
850:Drozitumab
778:for tumors
531:BMC Cancer
486:: 245181.
367:References
200:Molar mass
145:52G405U1E5
120:ChemSpider
100:CAS Number
1725:Phase III
1713:Withdrawn
1507:Naxitamab
1497:Matuzumab
1314:Humanized
1289:Rituximab
1254:Futuximab
1229:Cetuximab
1166:Solitomab
1126:Mitumomab
1116:Lilotomab
1096:Detumomab
1040:Votumumab
1030:Tovetumab
950:Nivolumab
915:Icrucumab
885:Ganitumab
269:Argentina
1201:Chimeric
1111:Igovomab
735:23110257
684:21300821
563:19519895
512:21941577
461:11859147
226:(verify)
79:ATC code
726:3478665
709:: 150.
643:9751737
611:Bibcode
554:2705377
537:: 180.
503:3177098
382:(2008)
353:History
161:Formula
1708:WHO-EM
733:
723:
682:
641:
631:
561:
551:
510:
500:
459:
328:mouse
253:Havana
240:Vaxira
73:Vaxira
54:Target
42:Source
1054:Mouse
793:Human
785:Tumor
634:21712
47:Mouse
731:PMID
680:PMID
639:PMID
559:PMID
508:PMID
484:2011
457:PMID
301:alum
263:and
257:Cuba
187:2048
181:1712
175:9922
169:6476
136:UNII
127:none
86:none
32:Type
721:PMC
711:doi
670:doi
666:186
629:PMC
619:doi
549:PMC
539:doi
498:PMC
488:doi
447:doi
443:168
276:GM3
267:in
251:at
209:.55
207:133
205:146
1748::
1721::
1613:/
729:.
719:.
705:.
701:.
678:.
664:.
660:.
637:.
627:.
617:.
607:95
605:.
601:.
589:^
579:.
557:.
547:.
533:.
529:.
506:.
496:.
482:.
478:.
455:.
441:.
437:.
407:.
255:,
193:50
1617:)
1609:(
821:)
817:(
768:e
761:t
754:v
737:.
713::
707:2
686:.
672::
645:.
621::
613::
583:.
565:.
541::
535:9
514:.
490::
463:.
449::
411:.
190:S
184:O
178:N
172:H
166:C
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.